tenofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals phosphonic acid derivatives 2592 147127-20-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tenofovir hydrate
  • tenofovir
  • tenefovir
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
  • Molecular weight: 287.22
  • Formula: C9H14N5O4P
  • CLOGP: -1.16
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 136.38
  • ALOGS: -2.19
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.83 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.93 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.80 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 2 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.177 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.945 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.195 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.776 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 37.280 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 52.590 % High 1
herg hERG pIC50 4.464 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.770 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.342 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 27.360 % High 1
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK7,NTRK1,NTRK2,PDK1,PDK2,PIK3CD,PRKDC,SIK2,STK33,TEK 26
kinase-selectivity-class AXL,CDK9,ERBB2,GRK2,MAP2K6,MAP3K21,PIK3CD 7
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.333 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.152 High 1
mppb Mouse plasma protein binding (% unbound) 84.510 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.256 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 42.800 % High 1
rh-clint Rat hepatocyte intrinsic clearance 2.460 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.860 % High 1
rppb Rat plasma protein binding (% unbound) 64.220 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 862.979 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 5, 2009 FDA HETERO DRUGS LTD
March 25, 2004 PMDA Japan Tobacco Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Maternal exposure during pregnancy 190.14 29.38 133 3176 359930 90265208
Drug interaction 159.54 29.38 108 3201 276345 90348793
Virologic failure 147.58 29.38 30 3279 2194 90622944
Drug resistance 134.18 29.38 48 3261 30401 90594737
Fanconi syndrome acquired 126.04 29.38 24 3285 1250 90623888
Foetal exposure during pregnancy 125.00 29.38 50 3259 42925 90582213
Immune reconstitution inflammatory syndrome 118.06 29.38 31 3278 6988 90618150
Viral mutation identified 109.18 29.38 23 3286 2002 90623136
Rebound effect 104.65 29.38 30 3279 9354 90615784
Abortion spontaneous 88.64 29.38 42 3267 54014 90571124
Exposure during pregnancy 87.31 29.38 71 3238 238339 90386799
Hepatitis B 85.88 29.38 22 3287 4497 90620641
Fanconi syndrome 76.26 29.38 17 3292 1926 90623212
Pathogen resistance 64.60 29.38 20 3289 8095 90617043
Hypophosphataemic osteomalacia 59.97 29.38 10 3299 241 90624897
Blood HIV RNA increased 59.92 29.38 12 3297 812 90624326
Hepatitis B reactivation 59.43 29.38 16 3293 3958 90621180
Premature delivery 57.10 29.38 28 3281 38734 90586404
Autoimmune hepatitis 55.86 29.38 19 3290 10332 90614806
Treatment noncompliance 52.21 29.38 29 3280 51698 90573440
Congenital umbilical hernia 50.41 29.38 9 3300 327 90624811
Birth mark 48.94 29.38 8 3301 170 90624968
Immune reconstitution inflammatory syndrome associated tuberculosis 46.78 29.38 9 3300 494 90624644
Renal tubular dysfunction 46.60 29.38 9 3300 504 90624634
Portal hypertension 43.45 29.38 13 3296 4688 90620450
Hypophosphataemia 42.15 29.38 17 3292 14837 90610301
Caesarean section 41.74 29.38 18 3291 18559 90606579
Hydrops foetalis 39.06 29.38 8 3301 605 90624533
Ergot poisoning 38.74 29.38 6 3303 89 90625049
Stillbirth 37.58 29.38 13 3296 7430 90617708
Glycosuria 37.34 29.38 9 3300 1433 90623705
Glucocorticoids increased 37.05 29.38 6 3303 120 90625018
Nephropathy toxic 34.21 29.38 14 3295 12674 90612464
Ultrasound antenatal screen 33.55 29.38 6 3303 220 90624918
Pregnancy on contraceptive 33.11 29.38 8 3301 1287 90623851
Tetany 32.13 29.38 9 3300 2575 90622563
Abortion induced 31.65 29.38 13 3296 11875 90613263

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psychiatric decompensation 382.66 20.89 96 6619 4126 42610494
Depression suicidal 325.22 20.89 80 6635 3165 42611455
Tearfulness 319.21 20.89 80 6635 3420 42611200
Immune reconstitution inflammatory syndrome 283.09 20.89 92 6623 10051 42604569
Depressive symptom 272.85 20.89 72 6643 3781 42610839
Psychomotor skills impaired 238.02 20.89 69 6646 5135 42609485
Lipodystrophy acquired 227.77 20.89 61 6654 3389 42611231
Paranoia 209.79 20.89 80 6635 13946 42600674
Drug interaction 203.75 20.89 229 6486 266770 42347850
Psychotic disorder 176.80 20.89 88 6627 29120 42585500
Mitochondrial toxicity 166.76 20.89 45 6670 2570 42612050
Progressive external ophthalmoplegia 157.70 20.89 38 6677 1373 42613247
Eyelid ptosis 152.20 20.89 52 6663 6609 42608011
Retinal toxicity 146.84 20.89 30 6685 497 42614123
Suicidal ideation 133.29 20.89 87 6628 48074 42566546
Hepatitis B 132.55 20.89 47 6668 6664 42607956
Psychomotor retardation 118.98 20.89 39 6676 4360 42610260
Acquired gene mutation 114.07 20.89 30 6685 1550 42613070
Fanconi syndrome acquired 106.04 20.89 30 6685 2040 42612580
Foetal exposure during pregnancy 103.64 20.89 74 6641 47237 42567383
Drug resistance 95.01 20.89 62 6653 34186 42580434
Pathogen resistance 88.99 20.89 41 6674 11409 42603211
Anxiety 77.00 20.89 94 6621 118466 42496154
Diplopia 72.03 20.89 43 6672 20273 42594347
Hepatic failure 64.28 20.89 51 6664 38049 42576571
Ophthalmoplegia 57.45 20.89 19 6696 2181 42612439
Ultrasound antenatal screen 56.94 20.89 14 6701 550 42614070
Gene mutation 53.07 20.89 17 6698 1764 42612856
Trisomy 18 51 20.89 14 6701 851 42613769
Hydrops foetalis 50.37 20.89 14 6701 891 42613729
Cleft lip and palate 49.97 20.89 14 6701 918 42613702
Fanconi syndrome 48.88 20.89 16 6699 1778 42612842
Meningitis cryptococcal 46.43 20.89 18 6697 3265 42611355
Depression 46.01 20.89 71 6644 111292 42503328
Birth mark 43.34 20.89 9 6706 162 42614458
Volvulus 43.18 20.89 15 6700 1998 42612622
Congenital umbilical hernia 41.90 20.89 10 6705 346 42614274
Hepatitis B reactivation 40.65 20.89 18 6697 4560 42610060
Drug-induced liver injury 39.92 20.89 39 6676 38234 42576386
Night blindness 39.48 20.89 9 6706 254 42614366
Adrenal suppression 36.26 20.89 11 6704 954 42613666
Nephropathy toxic 36.04 20.89 26 6689 16812 42597808
Superior mesenteric artery syndrome 35.29 20.89 7 6708 99 42614521
Treatment noncompliance 34.90 20.89 36 6679 37636 42576984
Portal hypertension 33.65 20.89 16 6699 4771 42609849
Hepatocellular carcinoma 30.74 20.89 18 6697 8176 42606444
Virologic failure 30.07 20.89 14 6701 3980 42610640
Hepatic encephalopathy 29.85 20.89 23 6692 16419 42598201
Secondary syphilis 29.61 20.89 6 6709 95 42614525
Osteomalacia 28.66 20.89 9 6706 875 42613745
Brachydactyly 25.41 20.89 6 6709 198 42614422
Renal tubular dysfunction 25.16 20.89 7 6708 447 42614173
Viral mutation identified 23.00 20.89 11 6704 3320 42611300
Hepatic fibrosis 21.77 20.89 12 6703 4860 42609760
Floppy eyelid syndrome 21.63 20.89 4 6711 38 42614582
Segmented hyalinising vasculitis 21.18 20.89 4 6711 43 42614577

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 449.32 21.50 127 9294 16099 110563779
Psychiatric decompensation 395.61 21.50 93 9328 5672 110574206
Drug interaction 343.62 21.50 306 9115 499877 110080001
Depression suicidal 331.92 21.50 78 9343 4746 110575132
Tearfulness 298.81 21.50 78 9343 7317 110572561
Depressive symptom 260.88 21.50 72 9349 8342 110571536
Psychomotor skills impaired 249.63 21.50 67 9354 6991 110572887
Lipodystrophy acquired 238.40 21.50 59 9362 4465 110575413
Hepatitis B 238.01 21.50 69 9352 9543 110570335
Paranoia 213.73 21.50 78 9343 22296 110557582
Psychotic disorder 184.58 21.50 89 9332 50848 110529030
Progressive external ophthalmoplegia 180.69 21.50 38 9383 1382 110578496
Mitochondrial toxicity 179.46 21.50 44 9377 3201 110576677
Fanconi syndrome acquired 177.27 21.50 43 9378 2991 110576887
Drug resistance 176.02 21.50 89 9332 56285 110523593
Retinal toxicity 174.80 21.50 38 9383 1621 110578257
Pathogen resistance 162.80 21.50 60 9361 17612 110562266
Eyelid ptosis 144.32 21.50 51 9370 13276 110566602
Acquired gene mutation 135.49 21.50 34 9387 2720 110577158
Fanconi syndrome 127.22 21.50 34 9387 3485 110576393
Suicidal ideation 121.80 21.50 84 9337 93853 110486025
Psychomotor retardation 112.50 21.50 37 9384 7755 110572123
Viral mutation identified 106.17 21.50 31 9390 4388 110575490
Virologic failure 102.68 21.50 31 9390 4921 110574957
Hepatitis B reactivation 97.93 21.50 33 9388 7451 110572427
Maternal exposure during pregnancy 92.25 21.50 111 9310 254772 110325106
Ultrasound antenatal screen 90.43 21.50 19 9402 687 110579191
Rebound effect 82.63 21.50 35 9386 14771 110565107
Hydrops foetalis 77.32 21.50 17 9404 764 110579114
Treatment noncompliance 75.65 21.50 57 9364 72933 110506945
Trisomy 18 69.78 21.50 15 9406 606 110579272
Hepatic failure 67.53 21.50 52 9369 68687 110511191
Cleft lip and palate 67.32 21.50 15 9406 717 110579161
Diplopia 65.20 21.50 42 9379 41852 110538026
Hypophosphataemic osteomalacia 63.17 21.50 13 9408 424 110579454
Abortion spontaneous 62.49 21.50 38 9383 34244 110545634
Nephropathy toxic 62.07 21.50 35 9386 27443 110552435
Gene mutation 60.64 21.50 19 9402 3410 110576468
Portal hypertension 60.40 21.50 24 9397 8613 110571265
Meningitis cryptococcal 58.39 21.50 20 9401 4742 110575136
Ophthalmoplegia 55.87 21.50 18 9403 3532 110576346
CSF HIV escape syndrome 53.84 21.50 11 9410 346 110579532
Blood HIV RNA increased 51.02 21.50 15 9406 2173 110577705
Foetal exposure during pregnancy 49.52 21.50 20 9401 7485 110572393
Hepatic encephalopathy 48.13 21.50 30 9391 28226 110551652
Anxiety 47.25 21.50 96 9325 344982 110234896
Adrenal suppression 45.65 21.50 13 9408 1683 110578195
Renal tubular dysfunction 43.83 21.50 11 9410 879 110578999
Night blindness 42.67 21.50 10 9411 599 110579279
Immune reconstitution inflammatory syndrome associated tuberculosis 41.99 21.50 11 9410 1043 110578835
Osteomalacia 41.97 21.50 12 9409 1575 110578303
Hypophosphataemia 41.38 21.50 29 9392 33153 110546725
Glycosuria 40.02 21.50 13 9408 2617 110577261
Drug-induced liver injury 39.66 21.50 50 9371 120017 110459861
Hepatocellular carcinoma 37.99 21.50 18 9403 9862 110570016
Caesarean section 35.04 21.50 19 9402 13798 110566080
Exposure during pregnancy 34.95 21.50 56 9365 167368 110412510
Superior mesenteric artery syndrome 34.39 21.50 7 9414 216 110579662
Secondary syphilis 32.84 21.50 6 9415 103 110579775
Glucocorticoids increased 31.88 21.50 6 9415 122 110579756
Ergot poisoning 31.47 21.50 6 9415 131 110579747
Autoimmune hepatitis 31.13 21.50 18 9403 14786 110565092
Malaise 29.91 21.50 10 9411 671809 109908069
Renal impairment 27.64 21.50 54 9367 188391 110391487
Hereditary optic atrophy 27.25 21.50 5 9416 88 110579790
Joint swelling 27.20 21.50 3 9418 442842 110137036
Pain 27.02 21.50 25 9396 954930 109624948
Renal tubular acidosis 25.82 21.50 11 9410 4704 110575174
Renal tubular necrosis 25.52 21.50 21 9400 30454 110549424
Hepatic cirrhosis 25.30 21.50 30 9391 67596 110512282
Depression 24.69 21.50 71 9350 317264 110262614
Acute kidney injury 24.48 21.50 113 9308 635317 109944561
Acute hepatic failure 24.19 21.50 22 9399 36446 110543432
Floppy eyelid syndrome 24.08 21.50 4 9417 38 110579840
Pregnancy on contraceptive 23.89 21.50 7 9414 1001 110578877
Lactic acidosis 23.54 21.50 34 9387 92777 110487101
Hepatitis C 23.07 21.50 14 9407 12559 110567319
Hepatic fibrosis 23.02 21.50 12 9409 8054 110571824
Cerebral toxoplasmosis 22.91 21.50 9 9412 3133 110576745
Drug level increased 22.70 21.50 24 9397 47695 110532183
Viral load increased 22.25 21.50 9 9412 3381 110576497
HIV infection 22.12 21.50 7 9414 1296 110578582
Tetany 21.71 21.50 9 9412 3595 110576283
Interstitial granulomatous dermatitis 21.51 21.50 5 9416 289 110579589

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Volvulus 41.95 32.16 8 12 104 113829

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:53756 HIV-1 reverse transcriptase inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Human immunodeficiency virus infection indication 86406008 DOID:526
Coronavirus infection off-label use 186747009
Prevention of HIV Infection after Exposure off-label use
Osteomalacia contraindication 4598005 DOID:10573
Hypophosphatemia contraindication 4996001
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Torsades de pointes contraindication 31722008
Depressive disorder contraindication 35489007
Fanconi syndrome contraindication 40488004 DOID:1062
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Prolonged QT interval contraindication 111975006
Chronic hepatitis C contraindication 128302006
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Paranoid disorder contraindication 191667009
Steatosis of liver contraindication 197321007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pathological fracture contraindication 268029009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Severe depression contraindication 310497006
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.23 acidic
pKa2 4.92 acidic
pKa3 4.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Reverse transcriptase Enzyme IC50 6.42 CHEMBL
Reverse transcriptase/RNaseH Enzyme IC50 6.42 CHEMBL
Capsid protein Structural EC50 6.62 CHEMBL

External reference:

IDSource
4021279 VUID
N0000148716 NUI
D06074 KEGG_DRUG
4021279 VANDF
C0384228 UMLSCUI
CHEBI:63716 CHEBI
TFO PDB_CHEM_ID
CHEMBL3989702 ChEMBL_ID
DB14126 DRUGBANK_ID
D000068698 MESH_DESCRIPTOR_UI
464205 PUBCHEM_CID
10948 IUPHAR_LIGAND_ID
99YXE507IL UNII
117466 RXNORM
d04774 MMSL
009357 NDDF
395264002 SNOMEDCT_US
422091007 SNOMEDCT_US
206184-49-8 SECONDARY_CAS_RN
99YXE507IL INXIGHT DRUGS

Pharmaceutical products:

None